Title: Risk factors associated with severe outcomes of COVID-19: A systematic rapid review to inform

national guidance on vaccine prioritization in Canada

Authors: Michelle Gates, PhD[1] (corresponding: michellegates85@gmail.com); Jennifer Pillay, MSc[1];

Aireen Wingert, MPH[1]; Samantha Guitard, MSc[1]; Sholeh Rahman, MSc[1]; Bernadette Zakher, MD[1]; Allison

Gates, PhD[1]; Lisa Hartling, PhD[1].

Affiliations: [1] Alberta Research Centre for Health Evidence, University of Alberta, Room 4-496 A, 4th

Floor Edmonton Clinic Health Academy, 11405-87 Avenue, Edmonton, Alberta, Canada, T6G 1C9

ABSTRACT

Background: To inform vaccine prioritization guidance in Canada, we systematically reviewed evidence

on the magnitude of association between risk factors and severe outcomes of COVID-19. The urgent

nature of this review necessitated an adapted methodology, which may serve as an exemplar for

reviews undertaken under strict timelines.

Methods: We updated our existing review by searching online databases and websites for cohort

studies providing multivariate adjusted associations. After piloting, one author screened studies and

extracted data. Two authors estimated the magnitude of association between exposures and outcomes

as little-to-no (odds, risk, or hazard ratio <2.0, or >0.50 for reduction), large (2.0-3.9, or 0.50-0.26 for

reduction), or very large (≥4.0, or ≤0.25 for reduction), and rated the evidence certainty using GRADE.

Results: Of 11,734 unique records we included 134 reports. There is probably (moderate certainty) at

least a large increase in mortality from COVID-19 among people aged 60-69 vs. <60 years (11 studies,

n=517,217), with ≥2 vs. no comorbidities (4 studies, n=189,608), and for people with (vs. without): Down

syndrome (1 study, n>8 million), type 1 and 2 diabetes (1 study, n>8 million), end-stage kidney disease

(1 study, n>8 million), motor neuron disease, multiple sclerosis, myasthenia gravis, or Huntington's

disease (as a grouping; 1 study, n>8 million). The magnitude of association with mortality is probably

very large for Down syndrome and may (low certainty) be very large for age 60-69 years, and diabetes.

There is probably little-to-no increase in severe outcomes with several cardiovascular and respiratory

conditions, and for adult males vs. females.

Conclusion: There is strong evidence to support at least a large increase in mortality from COVID-19

among older adults aged 60 to 69 years versus <60 years; people having two or more versus no

comorbidities; and for people affected by several pre-existing conditions. The methodology employed in

this review may provide an important exemplar for future syntheses undertaken under urgent timelines.

Systematic review registration: PROSPERO #CRD42021230185.

Keywords: Systematic review, COVID-19, coronavirus, risk factors

INTRODUCTION

The novel coronavirus disease 2019 (COVID-19) became a worldwide public health concern in early 2020

[1]. About 20% of affected people experience severe disease (e.g., requiring hospitalization) [2], and

some may have long-lasting symptoms or medical complications [3]. In late 2020, Health Canada

approved two vaccines for the prevention of COVID-19 (Pfizer-BioNTech COVID-19 Vaccine and Moderna

COVID-19 Vaccine); this was been followed by the approval of others and continued review of emerging

vaccine candidates [4]. As anticipated, vaccine distribution in Canada was initially constrained by

logistical challenges and limited supply [5-7], necessitating prioritization of populations for vaccination

[6, 7].

The National Advisory Committee on Immunization (NACI) developed preliminary vaccine prioritization

guidance in late 2020 "*for the efficient, effective and equitable allocation of safe, efficacious severe*

acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in the context of staggered arrival of

vaccines" [6, 7]. In addition to reviewing evidence on the burden of illness and vaccine characteristics,

NACI used its Ethics, Equity, Feasibility and Acceptability (EEFA) framework [8] and evidence-informed

Equity Matrix [9] to achieve the goal of their prioritization guidance. The Equity Matrix considers

biological and social risk factors (termed P^2ROGRESS And Other Factors, informed by the PROGRESS-Plus

model [10]) that may result in inequitable health outcomes across a population. The findings of a rapid

review of risk factors for severe outcomes of COVID-19 conducted by our research group [11] helped

populate the Equity Matrix, and informed NACI's guidance. This initial review found increasing age (>60

years and particularly >70 years) to be among the strongest risk factors for severe outcomes of COVID-

19 [11].

By early 2021, numerous additional relevant primary studies had been published. To inform subsequent

guidance statements [12, 13], we updated our rapid review to determine the magnitude of association

between P^{2}ROGRESS And Other Factors and severe outcomes of COVID-19. Though vaccines for COVID-

19 are now widely available to Canadians, this review serves an important archival function in informing

vaccine prioritization in regions where distribution is less far along. The methodology used in this review

may serve as an exemplar for similar high-priority scenarios where syntheses of large volumes of data

from primary studies are needed on expedited timelines.

METHODS

Review Approach

Detailed methods are in our pre-defined protocol (PROSPERO #CRD42021230185), and described briefly

herein. We followed traditional systematic review methods [14] with modifications to accommodate the

expedited timeline needed to inform NACI's guidance. Single experienced reviewers selected studies

and extracted data, with piloting to maintain rigour. We restricted the scope to large (>1,000

participants) studies with a high relevance to Canada.

The eligibility criteria were informed by stakeholders at NACI and the Public Health Agency of Canada;

these individuals were not involved in review conduct. This review is reported according to the

Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [15].

Eligibility criteria

Table 1 details our eligibility criteria. We included published (or accepted for publication) cohort studies

reporting multivariate adjusted associations between P^{2}ROGRESS And Other Factors (including but not

limited to age; gender identity or sex; disease/condition or disability; number of comorbidities; social

factors; other factors such as health behaviours) and severe outcomes of COVID-19 among: the general

population; people with COVID-19; people hospitalized with COVID-19; people with severe COVID-19 (as

defined by study authors; typically in an intensive care unit and/or mechanically ventilated); children in

any of the aforementioned populations. Outcomes of interest were: hospitalization; in-hospital length of

stay; ICU admission; ICU length of stay; mechanical ventilation; mortality (all-cause or case fatality);

severe disease (composite outcomes as defined by study authors, most often combining mortality with

ICU admission and/or mechanical ventilation); need for rehabilitation; stroke; kidney, liver, or cardiac

injury; generic functionality and/or disability (composite scores of validated scales); generic quality of

life (composite scores of validated scales). For age, we included data from all relevant comparisons,

however were interested specifically in the comparison of age 60-69 years vs. <60 years, as our previous

review already showed older age (particularly >70 years) to be among the strongest risk factors for

severe outcomes of COVID-19 [11]. Canadian reports of any design with any analysis type were eligible.

For social risk factors, we included only Canadian reports because these were considered as most

relevant by NACI.

[Table 1]

We applied criteria at the selection stage to include only the most informative studies. Studies needed

to take place in Organization for Economic Cooperation and Development (OECD) countries and include

≥1,000 participants (i.e., suitable for multivariate adjustment). Adjustment by age and sex was required

in all studies, except Canadian reports. Findings for age and/or sex required adjustment for at least one

pre-existing condition, and findings for most pre-existing conditions required adjustment for body mass

index (BMI). After screening, we loosened our selection criteria for studies among children, requiring a

sample size of ≥300 participants and adjustment by age and sex (but not BMI), as limited evidence was

available for this population.

When no primary studies were located on a risk factor of high relevance to NACI, we included systematic

reviews with broader selection criteria.

Literature search and study selection

Full details of the literature search are in Additional file 1. A research librarian searched online databases

(Ovid Medline® ALL 1946-, Epistemonikos COVID-19 in L-OVE Platform

[https://app.iloveevidence.com/loves] for individual predictors of outcomes; 2-3 December 2020) and

websites suggested by NACI (6 January - 3 February, 2021). We updated the Medline and website

searches in April 2021 for the pediatric population, immune compromise, and autoimmune conditions,

to further inform NACI's guidance for risk factors. We exported records to Endnote X9 (Clarivate

Analytics, Philadelphia, PA), removed duplicates and pre-prints, then uploaded the records to Covidence

systematic review platform (https://www.covidence.org/). After piloting (i.e., practice round with all

team members), a single experienced reviewer screened each record by title and abstract, then by full

text. A second reviewer was consulted if assistance was required to determine whether a study met the

selection criteria.

Following screening, gaps in evidence (i.e., no study meeting our criteria) were apparent for

asplenia/splenic dysfunction, cystic fibrosis, sickle cell disease, β-thalassemia, and learning disability

(potentially important based on inclusion in priority lists from other jurisdictions [16-19]). To locate

evidence for these, we scanned all studies excluded based on sample size (<1,000 participants),

preprints, and systematic reviews that we had located during our scoping exercises (September, 2020)

using Smart Searches in Endnote. On 18 February 2021, we conducted targeted searches in Ovid

Medline® ALL 1946- for studies and reviews on these risk factors.

Data extraction

After piloting (i.e., practice round with all team members), a single reviewer extracted data from each

study into Excel (v. 2016; Microsoft Corporation, Redmond, WA): study and population characteristics,

exposures, covariates, outcomes and their definitions, findings for multivariate associations. We held

regular team meetings to troubleshoot and ensure consistency. A second reviewer was consulted to

review and confirm ambiguous data presented within the included studies.

Quality assessment

Because we attempted to include only good quality studies (i.e., large sample size and with adequate

multivariate adjustment), we did not assess their quality using a formal tool. Instead, we recorded

potential risk of bias concerns (Additional file 2) during data extraction, and considered these during our

assessment of the certainty of evidence. The items (potential concerns) recorded included but were not

limited to**:** (a) lack of adjustment for social factors; (b) the expectation of attenuated magnitude of

association when the model was adjusted for laboratory values and/or symptoms; (c) for the

hospitalization outcome, potential for testing bias in certain populations (e.g., healthcare providers),

where the exposure group may have had less severe disease than those not exposed; (d) use of

historical, potentially inaccurate, data for risk factors or covariates.

Synthesis and drawing conclusions

Additional file 2 details our approach to synthesis and drawing conclusions. Results from the Canadian

studies, none of which met the criteria of having sufficiently adjusted analysis, were not included in the

main synthesis and are reported separately. We did not pool findings statistically for any outcome, due

to large heterogeneity in comparisons and measures of association, and at least some overlap in

populations across studies. Instead, two reviewers reached consensus on a best estimate of the

magnitude of association for each outcome-comparison across the relevant studies (based on adjusted

odds [aOR], risk, or hazard ratios): little-to-no (<2.0, or >0.5 for reduction), large (2.0-3.9, or 0.5-0.26 for

reduction), or very large (≥4.0, or ≤0.25 for reduction). Two reviewers assessed the certainty of evidence

for each exposure-outcome association, informed by elements of the Grading of Recommendations,

Assessment, Development and Evaluation approach [20], and agreed on the final rating. Given our focus

on prognostic variables, findings from observational studies for each outcome-comparison started at

high certainty [21], and were rated down for concerns related to risk of bias, inconsistency, imprecision,

and indirectness [20].

RESULTS

Included studies

Of 11,734 unique records identified, we included 134 reports (Figure 1) [22-155]. Full text exclusions are

listed at [https://doi.org/10.7939/DVN/W1M6OP]. We included one systematic review of case series for

β-thalassemia [142]. No studies or reviews were located with relevant findings for asplenia/splenic

dysfunction, cystic fibrosis, sickle cell disease, or learning disability. No study reported on long-term

outcomes. Table 2 shows a summary of the characteristics of the studies presenting multivariate

adjusted findings that were included in the main synthesis (n=123) [22-144]; full details by study,

including 11 Canadian reports [145-155], are in Additional file 3. The studies contributing multivariate

associations originated primarily from the United States (n=55), the United Kingdom (n=15), and Mexico

(n=12), and included more than 76 million participants (median 5,279; range 34 to 61,414,470).

[Figure 1]

[Table 2]

Associations between risk factors and outcomes

Based on stakeholder input, we considered people with confirmed COVID-19 to be the population of

highest relevance, thus have focused on these in our presentation of findings. When no data were

available from the COVID-19 population for a risk factor-outcome comparison, we relied on findings

from the general population. Table 3 summarizes the risk factors showing large or very large

multivariate-adjusted associations with severe outcomes. Additional file 2 includes findings for all risk

factors and populations investigated in the review. Data supporting the conclusions, including precise

associations presented in each included study, are available at

[https://doi.org/10.7939/DVN/W1M6OP].

[Table 3]

The certainty of evidence was moderate for at least a large increase in mortality from COVID-19 for

people aged 60-69 years versus <60 years (11 studies, n=517,217) [27, 57, 72, 78, 82, 97, 112, 113, 118,

121, 127, 135], people with two or more versus no comorbidities (4 studies, n=189,608) [57, 68, 121,

126], and for people with (versus without): Down syndrome (1 study, n>8 million) [41], type 1 and 2

diabetes (1 study, n>8 million) [41], end-stage kidney disease (1 study, n>8 million) [41]; motor neuron

disease, multiple sclerosis, myasthenia gravis, or Huntington's disease (as a grouping; 1 study, n>8

million) [41]. The magnitude of association with mortality is probably (moderate certainty) very large for

Down syndrome, and may (low certainty) be very large for age 60-69 years, and diabetes. We located no

evidence on the combination of conditions that would place people with two or more comorbidities at

increased risk.

The certainty of evidence was low for a large increase in mortality or hospitalization among: people with

cerebral palsy (1 study, n>8 million); major psychiatric disorder (schizophrenia, schizoaffective disorder,

or bipolar disorder, with drug use for the condition in the past 6 months; 1 study, n=11,122) [126];

obesity class III (BMI ≥40 kg/m^2) versus normal weight (1 study, n=1,612) [135]; Parkinson's disease (1

study, n>8 million) [41]; sickle cell disease or severe immunodeficiency (1 study, n>8 million) [41]; solid

organ transplant (2 studies, n=18,038 for mortality [126, 135]); transplant of any type (3 studies,

n=24,227 for hospitalization [58, 74, 126]); kidney transplant (1 study, n>8 million) [41]; recent bone

marrow or stem cell transplant (1 study, n>8 million) [41]; metastatic cancer among those <70 years (2

studies, n=38,377) [67, 135]; current or recent (past year) chemotherapy or radiotherapy (past 6

months; 1 study, n>8 million); vasculitis (1 study, n=4,543,249) [42]; pregnancy (any stage; 1 study,

n=409,462) [40]; frailty (2 studies, n=404,079) [89, 115]. The magnitude of association with mortality

may (low certainty) be very large for recent chemotherapy. There was moderate certainty for a large

increase in hospitalization with previous cerebrovascular accident (2 studies, n=12,376) [58, 138].

Among children, there was evidence of moderate certainty for a large increase in hospitalization among

those having two or more versus no chronic conditions (1 study, n=804) [52], and evidence of low

certainty for a large increase in mortality and hospitalization for children of Black versus White non-

Hispanic race/ethnicity (1 study, n=12,198) [106]. There was low certainty for a large reduction in

hospitalization for children 0-19 years versus adults aged 50-59 years (1 study, n=2,199) [126], and a

large increase in hospitalization for children with one versus no chronic conditions (1 study, n=790) [52],

and specifically for children with versus without immunodeficiency or immunosuppression (2 studies,

n=21,875) [55, 94], and hypertension (1 study, n=21,116) [94]. Additionally, there was evidence of low

certainty for a large increase in severe outcomes (ICU admission, mechanical ventilation, or 'severe

disease') among children with versus without: one or more chronic conditions (1 study, n=759 for

mechanical ventilation and severe disease [55]; 2 studies, n=1,341 for ICU admission), asthma (1 study,

n=21,116) [94], endocrine conditions (1 study, n=5,374) [32], metabolic conditions (1 study, n=5,374)

[32], and malignancy (1 study, n=5,374) [32].

There were several risk factors with moderate certainty evidence for little-to-no association with

increased severity of COVID-19, for example many pre-existing conditions (notably several

cardiovascular and respiratory conditions), and for adult males versus females (Additional file 2).

Table 4 shows the risk factors identified in Canadian reports and potential associations with severe

outcomes of COVID-19. All data collected from these studies are in Additional file 2. This evidence was

used primarily to draw conclusions about social factors, and was often descriptive and lacking

adjustment for important covariates. These studies showed the potential for a large increase in

mortality among people living in long-term care (6 reports, n≈2 million) [145, 146, 148, 151, 153], visible

minority groups (mainly South Asian, Chinese, Black, Filipino, Latin American, Arab, Southeast Asian,

West Asian, Korean, Japanese; 1 report, n=8,796) [154], and people living in the general population (off-

reserve) versus First Nations people living on-reserve (1 report, n=9,715) [147].

[Table 4]

DISCUSSION

This rapid systematic review provides a methodologically rigorous synthesis of a large volume of

emerging evidence on factors associated with severe outcomes of COVID-19. We identified strong

(moderate certainty) evidence of at least a large increase in mortality from COVID-19 among people

aged 60 to 69 versus <60 years (and over 70 years from our previous review [140]), people having two or

more versus no comorbidities, and for people affected by (versus unaffected): Down syndrome; type 1

and type 2 diabetes; end-stage kidney disease; motor neuron disease, multiple sclerosis, myasthenia

gravis, or Huntington's disease.

Our earlier review suggested a potentially large increase in severe outcomes among males versus

females, and for people with some pre-existing conditions (heart failure, dementia, liver disease) [11].

The evidence from the present review no longer supports this increased risk, underscoring the

importance of interpreting low certainty evidence cautiously, and of continually reviewing emerging

data to support vaccine prioritization guidance. Our update found relatively strong evidence for little-to-

no increase in severe outcomes for several pre-existing diseases, notably many cardiovascular and

respiratory conditions. In contrast, many jurisdictions have identified people with these conditions as

priorities for vaccination [16-19]. The reason for this is not fully clear, because the evidence on which

prioritization decisions are made is often not publically available, and such decisions are informed by

multiple considerations (e.g., local epidemiology, ethics, risk-benefit analyses, vaccine characteristics

and availability [6, 7, 156]) and varying levels of evidence.

A large reliance on unadjusted data may provide some explanation [157]. The data synthesized within

this review have the advantage of accounting for the impact of multiple co-existing conditions, social

and demographic factors. For example, in a large study (n=418,794) of the general population in the

United Kingdom [114], a large increase in hospitalization among people with heart failure (OR 2.24) and

chronic obstructive pulmonary disease (OR 2.67) was observed. Following adjustment for age, sex, social

factors, BMI, and other chronic conditions, these associations were substantially attenuated to the

range of little-to-no association (aOR 1.09 and 1.51, respectively) [114]. We observed similar

relationships in other studies. The thresholds of magnitude used to define 'large' and 'very large'

increases in severe outcomes may also impact the conditions prioritized. Finally, there are some rare

conditions (e.g., thalassemia, splenic dysfunction) for which to our knowledge, no large and well-

adjusted studies have been published. In these cases, governing bodies may need to rely on evidence

available for other infectious diseases, or from smaller cohorts suggesting the potential for increased

risk [19, 158-161].

The findings of this review, among other considerations, have informed NACI's vaccine prioritization

guidance. Though access to COVID-19 vaccines is now widespread in Canada, this review continues to

serve an important archival function. Our findings, particularly the developments that occurred between

our first review and the present one, underscore the importance of continuing to review emerging data

to provide up-to-date evidence of the highest possible certainty in times when urgent decision-making is

required (e.g., pandemics, emergencies). As an exemplar, at the time of our first review, few large, well-

adjusted analyses were available for children, who were not a population of high priority at that time.

However, in our latest update in April 2021, we located six new eligible studies that helped NACI to

develop evidence-informed guidance [32, 52, 55, 106, 123, 152]. Using the adapted methodology

described herein, we were able to provide timely empirical evidence to inform decision-making without

compromising aspects of rigour that were important to relevant stakeholders. This review may

therefore serve as an exemplar for abbreviated methodologies that may be undertaken to inform

decision-making in urgent situations.

Limitations

Because we used a rapid approach, there is a possibility of undetected errors in study selection or data

extraction. We mitigated this through piloting and engaging experienced reviewers. It was not

appropriate to pool the findings due to substantial heterogeneity and at least some overlap in

populations across studies; thus, it is possible that the qualitative estimates of measures of association

across studies may have been over- or underestimated. Though the findings are most applicable to

OECD countries, we often relied on data largely from the United States and other countries without

universal healthcare systems. We located no evidence relevant to long-term outcomes that met our

selection criteria.

Conclusion

There is strong evidence to support at least a large increase in mortality from COVID-19 among older

adults aged 60 to 69 years versus <60 years; people having two or more versus no comorbidities; and for

people affected by Down syndrome; type 1 and 2 diabetes; end-stage kidney disease; and motor neuron

disease, multiple sclerosis, myasthenia gravis, or Huntington's disease (as a grouping). The methodology

employed in this rapid systematic review may provide an important exemplar for future syntheses

undertaken under urgent timelines.

FIGURE TITLES AND LEGENDS

Figure 1. flow of records through the selection process

ADDITIONAL FILES

Name: Additional file 1

Format: .docx

Title: Search strategy

Description: Search strategy used to locate records for the systematic review

Name: Additional file 2

Format: .docx

Title: Approach to synthesis and all results

Description: Approach to data synthesis and full results for all populations analyzed

Name: Additional file 3

Format: .docx

Title: Detailed study characteristics

Description: Characteristics of the included studies

LIST OF ABBREVIATIONS

aOR   adjusted odds ratio

BMI   body mass index

COVID-19   novel coronavirus disease 2019

ICU   intensive care unit

RT-PCR   reverse transcription polymerase chain reaction

NACI   National Advisory Committee on Immunization

OECD   Organization for Economic Cooperation and Development

DECLARATIONS

Ethics approval and consent to participate

Not applicable.

Consent for publication

362   Not applicable.

Availability of data and materials

365   The data pertaining to the conclusions are available on reasonable request using the following link:

366   https://doi.org/10.7939/DVN/W1M6OP.

Competing interests

369   The authors have no competing interests to declare. Michelle Gates and Allison Gates are employees of

370   the Canadian Agency for Drugs and Technologies in Health (CADTH). The current work was unrelated to

371   their employment and CADTH had no role in the funding, design, or oversight of the work.

Funding

374   This study was completed under contract to the Public Health Agency of Canada, contract #4600001536.

375   LH is supported by a Tier 1 Canada Research Chair in knowledge synthesis and translation. The funders

376   had no role in the design of the study, data collection and analysis, preparation of the manuscript, nor

377   decision to submit for publication.

Authors' contributions

MG contributed to the conception and design of the work, selection of studies, data extraction, analysis

and interpretation of data, and drafted the initial version of the manuscript. JP contributed to the

conception and design of the work, analysis and interpretation of data, and revised versions of the

manuscript. AW, SG, SR, BZ, and AG contributed to the selection of studies, data extraction, organizing

data for analysis, and revised versions of the manuscript. LH contributed to the conception and design of

the work, methodological oversight, interpretation of findings, and revised versions of the manuscript.

All authors approved of the final version of the manuscript submitted and agree to be accountable for

all aspects of the work.

Acknowledgements

We thank Kelsey Young, Kelly Farrah, Shainoor Ismail, and Matthew Tunis from the NACI Secretariat for

expert input into the review's scope and eligibility criteria, and for reviewing the initial draft of the

manuscript; Sharon Bartholomew, Louise McRae, Anne-Marie Robert, Samina Aziz, Alain Demers,

Catherine Pelletier, Cynthia Robitaille, Larry Shaver, Helene Gardiner, and Dianne Zakaria from the

Public Health Agency of Canada for input into the necessary adjustment variables for analyses of chronic

diseases; Elizabeth Dennett and Erica Wright for developing and running literature searches; Andrew

Beck for assistance with screening; and Mackinna Hauff for article retrieval and document formatting.

REFERENCES

1.   World Health Organization. Coronavirus Disease 2019 (COVID-19): Situation Report - 51. Geneva,

Switzerland: World Health Organization; 2020. Available from: https://www.who.int/docs/default-

source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf

2.   World Health Organization. What we know about long-term effects of COVID-19: the latest on the

COVID-19 global situation & long-term sequelae; update 36. Geneva, Switzerland: World Health

Organization; 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/risk-

comms-updates/update-36-long-term-symptoms.pdf?sfvrsn=5d3789a6_2.

3.   Michelen M, Cheng V, Manoharan L, Elkheir N, Dagens D, Hastie C, et al. Characterising long term

407   Covid-19: a living systematic review. medRxiv. 2021:2020.12.08.20246025.

408   4.   Government of Canada. Drug and vaccine authorizations for COVID-19: List of applications

409   received. Ottawa, Canada: Government of Canada; 2021. Available from:

410   https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-

411   industry/drugs-vaccines-treatments/authorization/applications.html.

412   5.   Health Canada. What you need to know about the COVID-19 vaccine for Canada 2020. Ottawa,

413   Canada: Health Canada; 2020. Available from: https://www.canada.ca/en/public-

414   health/services/diseases/2019-novel-coronavirus-infection/awareness-resources/know-

415   vaccine.html.

416   6.   National Advisory Committee on Immunization. Preliminary guidance on key populations for early

417   COVID-19 immunization 2020. Ottawa, Canada; National Advisory Committee on Immunization;

418   2020. Available from: https://www.canada.ca/en/public-health/services/immunization/national-

419   advisory-committee-on-immunization-naci/guidance-key-populations-early-covid-19-

420   immunization.html.

421   7.   Ismail SJ, Zhao L, Tunis MC, Deeks SL, Quach C. Key populations for early COVID-19 immunization:

422   preliminary guidance for policy. CAMJ. 2020;192(48):E1620.

423   8.   Ismail SJ, Hardy K, Tunis MC, Young K, Sicard N, Quach C. A framework for the systematic

424   consideration of ethics, equity, feasibility, and acceptability in vaccine program recommendations.

425   Vaccine. 2020;38(36):5861-76.

426   9.   Ismail S, Tunis M, Zhao L, Quach C. Navigating inequities: a roadmap out of the pandemic. BMJ

427   2021;6:e004087.

428   10.   Evans T, Brown H. Road traffic crashes: operationalizing equity in the context of health sector

429   reform. Inj Control Saf Promot. 2003;10(1-2):11-2.

11. Wingert A, Pillay J, Gates M, Guitard S, Rahman S, Beck A, et al. Risk factors for severity of COVID-

19: a rapid review to inform vaccine prioritization in Canada. BMJ Open. 2021;11(5):e044684.

12. National Advisory Committee on Immunization. Guidance on the prioritization of key populations

for COVID-19 immunization (February 12, 2021). Ottawa, Canada; National Advisory Committee

on Immunization; 2021. Available from: https://www.canada.ca/en/public-

health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-

prioritization-key-populations-covid-19-vaccination.html.

13. National Advisory Committee on Immunization. Recommendations on the use of COVID-19

vaccines (last updated July 22, 2021). Ottawa, Canada; National Advisory Committee on

Immunization; 2021. Available from: https://www.canada.ca/content/dam/phac-

aspc/documents/services/immunization/national-advisory-committee-on-immunization-

naci/recommendations-use-covid-19-vaccines/recommendations-use-covid-19-vaccines-en.pdf.

14. Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane Handbook for

Systematic Reviews of Interventions, 2nd Edition. Chinchester, UK: John Wiley & Sons; 2019.

15. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020

statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

16. Centres for Disease Control and Prevention. People at increased risk and other people who need

to take extra precautions 2020; 2020. Available from: https://www.cdc.gov/coronavirus/2019-

ncov/need-extra-precautions/index.html.

17. Government of the United Kingdom Department of Health and Social Care. Joint Committee on

Vaccination and Immunisation: advice on priority groups for COVID-19 vaccination 2021; 2021.

Available from: https://www.gov.uk/government/publications/priority-groups-for-coronavirus-

covid-19-vaccination-advice-from-the-jcvi-30-december-2020/joint-committee-on-vaccination-

and-immunisation-advice-on-priority-groups-for-covid-19-vaccination-30-december-2020.

18.   Australian Government Department of Health. Advice for people at risk of coronavirus (COVID-19)

455   2021; 2021. Available from: https://www.health.gov.au/news/health-alerts/novel-coronavirus-

456   2019-ncov-health-alert/advice-for-people-at-risk-of-coronavirus-covid-19.

457   19.   Centers for Disease Control and Prevention. Science Brief: Evidence used to update the list of

458   underlying medical conditions that increase a person's risk of severe illness from COVID-19 2021;

459   2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlying-

460   evidence-table.html.

461   20.   Murad MH, Mustafa RA, Schünemann HJ, Sultan S, Santesso N. Rating the certainty in evidence in

462   the absence of a single estimate of effect. Evid Based Med. 2017;22(3):85-7.

463   21.   Iorio A, Spencer FA, Falavigna M, Alba C, Lang E, Burnand B, et al. Use of GRADE for assessment of

464   evidence about prognosis: rating confidence in estimates of event rates in broad categories of

465   patients. BMJ. 2015;350:h870.

466   22.   Adrish M, Chilimuri S, Mantri N, Sun H, Zahid M, Gongati S, et al. Association of smoking status

467   with outcomes in hospitalised patients with COVID-19. BMJ Open Resp Res. 2020;7(1):e000716.

468   23.   Ahlstrom B, Frithiof R, Hultstrom M, Larsson I-M, Strandberg G, Lipcsey M. The Swedish covid-19

469   intensive care cohort: Risk factors of ICU admission and ICU mortality. Acta Anaestesiol Scand.

470   2021;65(4):525-33.

471   24.   Alkhouli M, Nanjundappa A, Annie F, Bates MC, Bhatt DL. Sex differences in case fatality rate of

472   COVID-19: Insights from a multinational registry. Mayo Clin Proc. 2020;95(8):1613-20.

473   25.   Altschul DJ, Unda SR, Benton J, de la Garza Ramos R, Cezayirli P, Mehler M, et al. A novel severity

474   score to predict inpatient mortality in COVID-19 patients. Sci Rep. 2020;10(1):16726.

475   26.   Alvarez-Garcia J, Lee S, Gupta A, Cagliostro M, Joshi AA, Rivas-Lasarte M, et al. Prognostic impact

476   of prior heart failure in patients hospitalized with COVID-19. J Am Coll Cardiol. 2020;76(20):2334-

477   48.

27.   An C, Lim H, Kim D-W, Chang JH, Choi YJ, Kim SW. Machine learning prediction for mortality of

patients diagnosed with COVID-19: a nationwide Korean cohort study. Sci Rep. 2020;10(1):18716.

28.   Anantharaman A, Dusendang JR, Schmittdiel JA, Harzstark AL. SARS-CoV-2 Clinical outcomes in

patients with cancer in a large integrated health care system in Northern California. Oncol.

2021;26(3):e500-e4.

29.   Anderson MR, Geleris J, Anderson DR, Zucker J, Nobel YR, Freedberg D, et al. Body mass index and

risk for intubation or death in SARS-CoV-2 infection: a retrospective cohort study. Ann Intern Med.

2020;173(10):782-90.

30.   Attaway AA, Zein J, Hatipoglu US. SARS-CoV-2 infection in the COPD population is associated with

increased healthcare utilization: An analysis of Cleveland clinic's COVID-19 registry.

EClinicalMedicine. 2020;26:100515.

31.   Azar KMJ, Shen Z, Romanelli RJ, Lockhart SH, Smits K, Robinson S, et al. Disparities in outcomes

among COVID-19 patients in a large health care system in California. Health Aff. 2020;39(7):1253-

62.

32.   Bailey LC, Razzaghi H, Burrows EK, Bunnell HT, Camacho PEF, Christakis DA, et al. Assessment of

135794 pediatric patients tested for severe acute respiratory syndrome coronavirus 2 across the

United States. JAMA Pediatr. 2021;175(2):176-84.

33.   Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, et al. Associations of type 1 and type 2

diabetes with COVID-19-related mortality in England: A whole-population study. Lancet Diabetes

Endocrinol. 2020;8(10):813-22.

34.   Bennett KE, Mullooly M, O'Loughlin M, Fitzgerald M, O'Donnell J, O'Connor L, et al. Underlying

conditions and risk of hospitalisation, ICU admission and mortality among those with COVID-19 in

Ireland: A national surveillance study. Lancet. 2021;5(100097).

35. Berenguer J, Ryan P, Rodriguez-Bano J, Jarrin I, Carratala J, Pachon J, et al. Characteristics and

predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. Clin

Mircobiol Infect. 2020;26(11):1525-36.

36. Bowe B, Cai M, Xie Y, Gibson AK, Maddukuri G, Al-Aly Z. Acute kidney injury in a national cohort of

hospitalized US veterans with COVID-19. Clin J Am Soc Nephrol. 2021;16(1):14-25.

37. Bravi F, Flacco ME, Carradori T, Volta CA, Cosenza G, De Togni A, et al. Predictors of severe or

lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor

Blockers, in a sample of infected Italian citizens. PloS One. 2020;15(6):e0235248.

38. Carter B, Collins JT, Barlow-Pay F, Rickard F, Bruce E, Verduri A, et al. Nosocomial COVID-19

infection: examining the risk of mortality. The COPE-Nosocomial Study (COVID in Older PEople). J

Hosp Infect. 2020;106(2):376-84.

39. Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao S, et al. AKI in Hospitalized Patients with

COVID-19. J Am Soc Nephrol. 2020;106(2):376-384.

40. Chhiba KD, Patel GB, Vu THT, Chen MM, Guo A, Kudlaty E, et al. Prevalence and characterization of

asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin Immunol.

2020;146(2):307-14.e4.

41. Clift AK, Coupland CAC, Keogh RH, Hemingway H, Hippisley-Cox J. COVID-19 mortality risk in Down

syndrome: Results from a cohort study Of 8 million adults. Ann Intern Med. 2020;M20-4986.

42. Cordtz R, Lindhardsen J, Soussi BG, Vela J, Uhrenholt L, Westermann R, et al. Incidence and

severeness of COVID-19 hospitalisation in patients with inflammatory rheumatic disease: a

nationwide cohort study from Denmark. Rheumatol. 2020; keaa897.

43. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology,

clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective

cohort study. Lancet. 2020;395(10239):1763-70.

44.   Czernichow S, Beeker N, Rives-Lange C, Guerot E, Diehl JL, Katsahian S, et al. Obesity doubles

mortality in patients hospitalized for SARS-CoV-2 in Paris hospitals, France: a cohort study on 5795

patients. Obesity. 2020;28(12):2282-9.

45.   D'Silva KM, Jorge A, Cohen A, McCormick N, Zhang Y, Wallace ZS, et al. COVID-19 outcomes in

patients with Systemic Autoimmune Rheumatic Diseases (SARDs) compared to the general

population: A US multi-center comparative cohort study. Arthritis Rheumatol. 2021;73(6):914-20.

46.   de Azambuja E, Brandao M, Wildiers H, Laenen A, Aspeslagh S, Fontaine C, et al. Impact of solid

cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19:

a nationwide, population-based analysis. ESMO Open. 2020;5(5):e000947.

47.   Dennis JM, Mateen BA, Sonabend R, Thomas NJ, Patel KA, Hattersley AT, et al. Type 2 diabetes and

COVID-19-related mortality in the critical care setting: a national cohort study in England, March-

July 2020. Diabetes care. 2021;44(1):50-7.47.

48.   Denova-Gutiérrez E, Lopez-Gatell H, Alomia-Zegarra JL, López-Ridaura R, Zaragoza-Jimenez CA,

Dyer-Leal DD, et al. The association between obesity, type 2 diabetes, and hypertension with

severe COVID-19 on admission among Mexicans. Obesity. 2020;28(10):1826-32.

49.   Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK

patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol:

prospective observational cohort study. BMJ. 2020;369:m1985.

50.   Ellington S, Strid P, Tong VT, Woodworth K, Galang R, Zambrano LD, et al. Characteristics of

women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status

— United States, January 22–June 7, 2020. Obstet Gynecol Surv. 2020;75(11):664-6

51.   Esme M, Koca M, Dikmeer A, Balci C, Ata N, Dogu BB, et al. Older adults with coronavirus disease

2019; a nationwide study in Turkey. J Gerontol. 2021. 76(3):e68-75.

52.   Floyd GC, Dudley JW, Xiao R, Feudtner C, Taquechel K, Miller K, et al. Prevalence of asthma in

hospitalized and non-hospitalized children with COVID-19. J Allergy Clin Immunol Pract.

2021;9(5):2077-9.e2.

53.   Fond G, Pauly V, Leone M, Llorca P-M, Orleans V, Loundou A, et al. Disparities in intensive care

unit admission and mortality among patients with schizophrenia and COVID-19: a national cohort

study. Schizophr Bull. 2020;sba158.

54.   Fresan U, Guevara M, Elia F, Albeniz E, Burgui C, Castilla J, et al. Independent role of morbid

obesity as a risk factor for COVID-19 hospitalization: a Spanish population-based cohort study.

Obesity. 2021;29(1):29-37.54.

55.   Garazzino S, Lo Vecchio A, Pierantoni L, Calo Carducci FI, Marchetti F, Meini A, et al. Epidemiology,

clinical features and prognostic factors of pediatric SARS-CoV-2 infection: Results from an Italian

multicenter Study. Front Pediatr. 2021;9:649358.

56.   Geretti AM, Stockdale AJ, Kelly SH, Cevik M, Collins S, Waters L, et al. Outcomes of COVID-19

related hospitalization among people with HIV in the ISARIC WHO Clinical Characterization

Protocol (UK): a prospective observational study. Clin Infect Dis. 2020;ciaa1605.

57.   Giorgi Rossi P, Marino M, Formisano D, Venturelli F, Vicentini M, Grilli R, et al. Characteristics and

outcomes of a cohort of COVID-19 patients in the Province of Reggio Emilia, Italy. PloS One.

2020;15(8):e0238281.

58.   Gottlieb M, Sansom S, Frankenberger C, Ward E, Hota B. Clinical course and factors associated

with hospitalization and critical illness among COVID-19 patients in Chicago, Illinois. Acad Emerg

Med. 2020;27(10):963-73.

59.   Götzinger F, Santiago-Garcia B, Noguera-Julian A, Lanaspa M, Lancella L, Calo Carducci FI, et al.

COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet

Child Adolesc Health. 2020;4(9):653-61.

60.   Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk factors associated with

573   mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern

574   Med. 2020;180(10):1345-55.

575   61.   Guerrero-Torres L, Caro-Vega Y, Crabtree-Ramirez B, Sierra-Madero JG. Clinical characteristics and

576   mortality of healthcare workers with SARS-CoV-2 infection in Mexico City. Clin Infect Dis.

577   2020;ciaa1465.

578   62.   Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors associated with

579   death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med.

580   2020;180(11):1436-46.

581   63.   Gupta S, Coca SG, Chan L, Melamed ML, Brenner SK, Hayek SS, et al. AKI treated with renal

582   replacement therapy in critically ill patients with COVID-19. J Am Soc Nephrol. 2020;32(1):161-76.

583   64.   Hajifathalian K, Krisko T, Mehta A, Kumar S, Schwartz R, Fortune B, et al. Gastrointestinal and

584   hepatic manifestations of 2019 novel coronavirus disease in a large cohort of infected patients

585   from New York: clinical implications. Gastroentero. 2020;159(3):1137-1140.e2.

586   65.   Hamer M, Gale CR, Kivimaki M, Batty GD. Overweight, obesity, and risk of hospitalization for

587   COVID-19: A community-based cohort study of adults in the United Kingdom. Proc Natl Acad Sci

588   USA. 2020;117(35):21011-3.

589   66.   Hamer M, Kivimaki M, Gale CR, David Batty G. Lifestyle risk factors, inflammatory mechanisms,

590   and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK. Brain

591   Behv Immun. 2020;87:184-7.

592   67.   Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities associated with

593   mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical

594   record analysis. PLoS Med. 2020;17(9):e1003321.

595   68.   Hernández-Vásquez A, Azañedo D, Vargas-Fernández R, Bendezu-Quispe G. Association of

596   comorbidities with pneumonia and death among COVID-19 patients in Mexico: a nationwide

597   cross-sectional study. J Prev Med Public Health. 2020;53(4):211-9.

598   69.   Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney injury in patients

599   hospitalized with COVID-19. Kidney Int. 2020;98(1):209-18.

600   70.   Huh K, Lee R, Ji W, Kang M, Hwang IC, Lee DH, et al. Impact of obesity, fasting plasma glucose

601   level, blood pressure, and renal function on the severity of COVID-19: A matter of sexual

602   dimorphism? Diabetes Res Clin Pract. 2020;170:108515.

603   71.   Iaccarino G, Grassi G, Borghi C, Ferri C, Salvetti M, Volpe M, et al. Age and multimorbidity predict

604   death among COVID-19 patients: results of the SARS-RAS study of the Italian Society of

605   Hypertension. Hypertension. 2020;76(2):366-72.

606   72.   Ioannou GN, Locke E, Green P, Berry K, O'Hare AM, Shah JA, et al. Risk factors for hospitalization,

607   mechanical ventilation, or death among 10131 US veterans With SARS-CoV-2 infection. JAMA

608   Netw Open. 2020;3(9):e2022310.

609   73.   Izurieta HS, Graham DJ, Jiao Y, Hu M, Lu Y, Wu Y, et al. natural history of coronavirus disease 2019:

610   risk factors for hospitalizations and deaths among >26 Million US Medicare Beneficiaries. J Infect

611   Dis. 2021;223(6):945-56.

612   74.   Izzy S, Tahir Z, Cote DJ, Al Jarrah A, Roberts MB, Turbett S, et al. Characteristics and outcomes of

613   Latinx patients with COVID-19 in comparison with other ethnic and racial groups. Open Forum

614   Infect Dis. 2020;7(10):ofaa401.

615   75.   Jakob CEM, Borgmann S, Duygu F, Behrends U, Hower M, Merle U, et al. First results of the "Lean

616   European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)". Infection. 2021;49(1):63-73.

76.   Ji W, Huh K, Kang M, Hong J, Bae GH, Lee R, et al. Effect of underlying comorbidities on the

infection and severity of COVID-19 in Korea: a nationwide case-control study. J Korean Med Sci.

2020;35(25):e237.

77.   Jiménez E, Fontán-Vela M, Valencia J, Fernandez-Jimenez I, Álvaro-Alonso EA, Izquierdo-García E,

et al. Characteristics, complications and outcomes among 1549 patients hospitalised with COVID-

19 in a secondary hospital in Madrid, Spain: a retrospective case series study. BMJ Open.

2020;10(11):e042398.

78.   Kabarriti R, Brodin NP, Maron MI, Guha C, Kalnicki S, Garg MK, et al. Association of race and

ethnicity with comorbidities and survival among patients with COVID-19 at an urban medical

center in New York. JAMA Netw Open. 2020;3(9):e2019795.

79.   Kaeuffer C, Le Hyaric C, Fabacher T, Mootien J, Dervieux B, Ruch Y, et al. Clinical characteristics

and risk factors associated with severe COVID-19: prospective analysis of 1,045 hospitalised cases

in North-Eastern France, March 2020. Euro Surveill. 2020;25(48):2000895.

80.   Kim L, Garg S, O'Halloran A, Whitaker M, Pham H, Anderson EJ, et al. Risk Factors for intensive

care unit admission and in-hospital mortality among hospitalized adults identified through the U.S.

Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-

NET). Clin Infect Dis. 2020;ciaa1012.

81.   Kim T, Roslin M, Wang JJ, Kane J, Hirsch JS, Ji Kim E, et al. Body mass index as a risk factor for

clinical outcomes in patients hospitalized with COVID-19 in New York. Obesity. 2020;29(2):279-

284.

82.   King JT Jr., Yoon JS, Rentsch CT, Tate JP, Park LS, Kidwai-Khan F, et al. Development and validation

of a 30-day mortality index based on pre-existing medical administrative data from 13,323 COVID-

19 patients: The Veterans Health Administration COVID-19 (VACO) Index. PloS One.

2020;15(11):e0241825.

83. Kjeldsen J, Nielsen J, Ellingsen T, Knudsen T, Nielsen RG, Larsen MD, et al. Outcome of COVID-19 in

hospitalized patients with chronic inflammatory diseases. A population based national register

study in Denmark. J Autoimmun. 2021;120:102632.

84. Klang E, Kassim G, Soffer S, Freeman R, Levin MA, Reich DL. Morbid obesity as an independent risk

factor for covid-19 mortality in hospitalized patients younger than 50. Obesity. 2020;28(9):1595-9.

85. Ko JY, Danielson ML, Town M, Derado G, Greenlund KJ, Daily Kirley P, et al. Risk factors for COVID-

19-associated hospitalization: COVID-19-associated hospitalization surveillance network and

behavioral risk factor surveillance system. Clin Infect Dis. 2020;ciaa1419.

86. Kolhe NV, Fluck RJ, Selby NM, Taal MW. Acute kidney injury associated with COVID-19: A

retrospective cohort study. PLoS Med. 2020;17(10):e1003406.

87. Kragholm K, Andersen MP, Gerds TA, Butt JH, Ostergaard L, Polcwiartek C, et al. Association

between male sex and outcomes of Coronavirus Disease 2019 (Covid-19) - a Danish nationwide,

register-based study. Clin Infect Dis. 2020;ciaa924.

88. Kummer BR, Klang E, Stein LK, Dhamoon MS, Jette N. History of stroke is independently associated

with in-hospital death in patients with COVID-19. Stroke. 2020;51(10):3112-4.

89. Kundi H, Cetin EHO, Canpolat U, Aras S, Celik O, Ata N, et al. The role of frailty on adverse

outcomes among older patients with COVID-19. J Infect. 2020;81(6):944-51.

90. Lassale C, Gaye B, Hamer M, Gale CR, Batty GD. Ethnic disparities in hospitalisation for COVID-19

in England: The role of socioeconomic factors, mental health, and inflammatory and pro-

inflammatory factors in a community-based cohort study. Brain Behav Immun. 2020;88;44-9.

91. Lee S-G, Park GU, Moon YR, Sung K. Clinical characteristics and risk factors for fatality and severity

in patients with coronavirus disease in korea: a nationwide population-based retrospective study

using the Korean Health Insurance Review and Assessment Service (HIRA) Database. Int J Environ

Res Public Health. 2020;17(22):8559.

92. Lee SH, Park S-Y, Seon J-Y, Jeon W-H, Nam S-I, Park J-H, et al. Intensive care unit capacity and its

associated risk factors during the COVID-19 surge in the Republic of Korea: analysis using

nationwide health claims data. Risk Manag Healthc Policy. 2020;13:2571-81.

93. Lee SW, Yang JM, Moon SY, Yoo IK, Ha EK, Kim SY, et al. Association between mental illness and

COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study. Lancet

Psych. 2020;7(12):1025-31.

94. Leon-Abarca JA. Obesity and immunodeficiencies are the main pre-existing conditions associated

with mild to moderate COVID-19 in children. Pediatr Obes. 2020;15(12):e12713.

95. Loffi M, Piccolo R, Regazzoni V, Di Tano G, Moschini L, Robba D, et al. Coronary artery disease in

patients hospitalised with Coronavirus disease 2019 (COVID-19) infection. Open Heart. 2020;7(2).

96. Ludvigsson JF, Axelrad J, Halfvarson J, Khalili H, Larsson E, Lochhead P, et al. Inflammatory bowel

disease and risk of severe COVID-19: A nationwide population-based cohort study in Sweden.

United European Gastroenterol J. 2021;9(2):177-92.

97. Lunski MJ, Burton J, Tawagi K, Maslov D, Simenson V, Barr D, et al. Multivariate mortality analyses

in COVID-19: comparing patients with cancer and patients without cancer in Louisiana. Cancer.

2021;127(2):266-74.

98. Mallow PJ, Belk KW, Topmiller M, Hooker EA. Outcomes of hospitalized COVID-19 patients by risk

factors: results from a United States hospital claims database. J Health Econ Outcomes Res.

2020;7(2):165-74.

99. Mancilla-Galindo J, Vera-Zertuche JM, Navarro-Cruz AR, Segura-Badilla O, Reyes-Velazquez G,

Tepepa-Lopez FJ, et al. Development and validation of the patient history COVID-19 (PH-Covid19)

scoring system: a multivariable prediction model of death in Mexican patients with COVID-19.

Epidemiol Infect. 2020;148:e286.

688 100. Martinez-Portilla RJ, Smith ER, He S, Torres-Torres J, Espino-Y-Sosa S, Solis-Paredes JM, et al.

689    Young pregnant women are also at an increased risk of mortality and severe illness due to

690    coronavirus disease 2019: analysis of the Mexican National Surveillance Program. Am J Obstet

691    Gynecol. 2021;224(4):404-7.

692 101. Martinez-Portilla RJ, Sotiriadis A, Chatzakis C, Torres-Torres J, Espino Y Sosa S, Sandoval-

693    Mandujano K, et al. Pregnant women with SARS-CoV-2 infection are at higher risk of death and

694    pneumonia: propensity score matched analysis of a nationwide prospective cohort (COV19Mx).

695    Ultrasound Obstet Gynecol. 2021;57(2):224-31.

696 102. Mikami T, Miyashita H, Yamada T, Harrington M, Steinberg D, Dunn A, et al. Risk factors for

697    mortality in patients with COVID-19 in New York City. J Gen Intern Med. 2020;36:17-26.

698 103. Miller J, Fadel RA, Tang A, Perrotta G, Herc E, Soman S, et al. The impact of sociodemographic

699    factors, comorbidities and physiologic response on 30-day mortality in COVID-19 patients in

700    Metropolitan Detroit. Clin Infect Dis. 2020;ciaa1420.

701 104. Misra-Hebert AD, Jehi L, Ji X, Nowacki AS, Gordon S, Terpeluk P, et al. Impact of the COVID-19

702    pandemic on healthcare workers' risk of infection and outcomes in a large, integrated health

703    system. J Gen Intern Med. 2020;35(11):3293-301.

704 105. Molnar MZ, Bhalla A, Azhar A, Tsujita M, Talwar M, Balaraman V, et al. Outcomes of critically ill

705    solid organ transplant patients with COVID-19 in the United States. Am J Transplant.

706    2020;20(11):3061-71.

707 106. Moreira A, Chorath K, Rajasekaran K, Burmeister F, Ahmed M, Moreira A. Demographic predictors

708    of hospitalization and mortality in US children with COVID-19. Eur J Pediatr. 2021;180(5):1659-63.

709 107. Murillo-Zamora E, Hernandez-Suarez CM. Survival in adult inpatients with COVID-19. Public

710    Health. 2021;190:1-3.

711   108.   Nachtigall I, Lenga P, Jozwiak K, Thurmann P, Meier-Hellmann A, Kuhlen R, et al. Clinical course

712   and factors associated with outcomes among 1904 patients hospitalized with COVID-19 in

713   Germany: an observational study. Clin Microbiol Infect. 2020;26(12):1663-9.

714   109.   Nair V, Jandovitz N, Hirsch JS, Abate M, Satapathy SK, Roth N, et al. An early experience on the

715   effect of solid organ transplant status on hospitalized COVID-19 patients. Am J Transplant.

716   2020;21(7):2522-31.

717   110.   Ng JH, Hirsch JS, Wanchoo R, Sachdeva M, Sakhiya V, Hong S, et al. Outcomes of patients with

718   end-stage kidney disease hospitalized with COVID-19. Kidney Int. 2020;98(6);1530-9.

719   111.   Nijman G, Wientjes M, Ramjith J, Janssen N, Hoogerwerf J, Abbink E, et al. Risk factors for in-

720   hospital mortality in laboratory-confirmed COVID-19 patients in the Netherlands: A competing risk

721   survival analysis. PloS One. 2021;16(3):e0249231.

722   112.   Parra-Bracamonte GM, Lopez-Villalobos N, Parra-Bracamonte FE. Clinical characteristics and risk

723   factors for mortality of patients with COVID-19 in a large data set from Mexico. Ann Epidemiol.

724   2020;52:93-8.e2.

725   113.   Parra-Bracamonte GM, Parra-Bracamonte FE, Lopez-Villalobos N, Lara-Rivera AL. Chronic kidney

726   disease is a very significant comorbidity for high risk of death in patients with COVID-19 in Mexico.

727   Nephrol. 2020. 26(3):248-51.

728   114.   Patel AP, Paranjpe MD, Kathiresan NP, Rivas MA, Khera AV. Race, socioeconomic deprivation, and

729   hospitalization for COVID-19 in English participants of a national biobank. Int J Equity Health.

730   2020;19(1):114.

731   115.   Petermann-Rocha F, Hanlon P, Gray SR, Welsh P, Gill JMR, Foster H, et al. Comparison of two

732   different frailty measurements and risk of hospitalisation or death from COVID-19: findings from

733   UK Biobank. BMC Med. 2020;18(1):355.

116. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors associated with

hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New

York City: prospective cohort study. BMJ. 2020;369:m1966.

117. Pinto C, Berselli A, Mangone L, Damato A, Iachetta F, Foracchia M, et al. SARS-CoV-2 positive

hospitalized cancer patients during the Italian outbreak: the cohort study in Reggio Emilia. Biology.

2020;9(8):181.

118. Poletti P, Tirani M, Cereda D, Trentini F, Guzzetta G, Marziano V, et al. Age-specific SARS-CoV-2

infection fatality ratio and associated risk factors, Italy, February to April 2020. Euro Surveill.

2020;25(31):2001383.

119. Polverino F, Stern DA, Ruocco G, Balestro E, Bassetti M, Candelli M, et al. Comorbidities,

cardiovascular therapies, and COVID-19 mortality: a nationwide, Italian observational study

(ItaliCO). Front Cardiovasc Med. 2020;7:585866.

120. Portolés J, Marques M, López-Sánchez P, de Valdenebro M, Muñez E, Serrano ML, et al. Chronic

kidney disease and acute kidney injury in the COVID-19 Spanish outbreak. Nephrol Dial Transplant.

2020;35(8):1353-61.

121. Poulson M, Geary A, Annesi C, Allee L, Kenzik K, Sanchez S, et al. National disparities in COVID-19

outcomes between Black and White Americans. J Natl Med Assoc. 2020; in press.

122. Prado-Galbarro FJ, Sanchez-Piedra C, Gamino-Arroyo AE, Cruz-Cruz C. Determinants of survival

after severe acute respiratory syndrome coronavirus 2 infection in Mexican outpatients and

hospitalised patients. Pub Health. 2020;189:66-72.

123. Preston LE, Chevinsky JR, Kompaniyets L, Lavery AM, Kimball A, Boehmer TK, et al. Characteristics

and Disease Severity of US Children and Adolescents Diagnosed With COVID-19. JAMA Netw Open.

2021;4(4):e215298.

757 124. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and mortality among black patients

758   and white patients with Covid-19. N Engl J Med. 2020;382:2534-43.

759 125. Rapp J, Lieberman-Cribbin W, Tuminello S, Taioli E. Male sex, severe obesity, older age, and

760   chronic kidney disease are associated with COVID-19 severity and mortality in New York City.

761   Chest. 2020;159(1):112-5.

762 126. Reilev M, Kristensen KB, Pottegard A, Lund LC, Hallas J, Ernst MT, et al. Characteristics and

763   predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for

764   SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol. 2020;49(5):1468-81.

765 127. Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King JT, Jr., Skanderson M, et al. Patterns of COVID-19

766   testing and mortality by race and ethnicity among United States veterans: A nationwide cohort

767   study. PLoS Med. 2020;17(9):e1003379.

768 128. Rey JR, Caro-Codón J, Rosillo SO, Iniesta AM, Castrejon-Castrejón S, Marco-Clement I, et al. Heart

769   failure in COVID-19 patients: prevalence, incidence and prognostic implications. Eur J Heart Fail.

770   2020:101002/ejhf.1990.

771 129. Ríos-Silva M, Murillo-Zamora E, Mendoza-Cano O, Trujillo X, Huerta M. COVID-19 mortality among

772   pregnant women in Mexico: A retrospective cohort study. J Glob Health. 2020;10(2):020512.

773 130. Rodilla E, Saura A, Jiménez I, Mendizábal A, Pineda-Cantero A, Lorenzo-Hernández E, et al.

774   Association of Hypertension with all-cause mortality among hospitalized patients with COVID-19. J

775   Clin Med. 2020;9(10):3136.

776 131. Samuels S, Niu J, Sareli C, Eckardt P. The epidemiology and predictors of outcomes among

777   confirmed COVID-19 cases in a large community healthcare system in south Florida. J Community

778   Health. 2021;46(4):822-31.

779   132.   Sapey E, Gallier S, Mainey C, Nightingale P, McNulty D, Crothers H, et al. Ethnicity and risk of death

780   in patients hospitalised for COVID-19 infection in the UK: an observational cohort study in an

781   urban catchment area. BMJ Open Resp Res. 2020;7(1):e000644.

782   133.   Shah ASV, Wood R, Gribben C, Caldwell D, Bishop J, Weir A, et al. Risk of hospital admission with

783   coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort

784   study. BMJ. 2020;371:m3582.

785   134.   Shah V, Ko Ko T, Zuckerman M, Vidler J, Sharif S, Mehra V, et al. Poor outcome and prolonged

786   persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's

787   College Hospital experience. Br J Haematol. 2020;190(5):279-82.

788   135.   Tartof SY, Qian L, Hong V, Wei R, Nadjafi RF, Fischer H, et al. Obesity and mortality among patients

789   diagnosed with COVID-19: results from an integrated health care organization. Ann Intern Med.

790   2020;173(10):773-81.

791   136.   Ungaro RC, Agrawal M, Park S, Hirten R, Colombel J-F, Twyman K, et al. Autoimmune and chronic

792   inflammatory disease patients with COVID-19. ACR Open Rheumatol. 2021;3(2):111-5.

793   137.   Valenzuela RG, Michelen Y, Bracey A, Cruz P, Fombonne B, Fries BC, et al. Outcomes in Hispanics

794   With COVID-19 are similar to those of Caucasian patients in suburban New York. Acad Emerg Med.

795   2020;27(12):1260-9.

796   138.   van Gerwen M, Alsen M, Little C, Barlow J, Genden E, Naymagon L, et al. Risk factors and

797   outcomes of COVID-19 in New York City; a retrospective cohort study. J Med Virol.

798   2020;93(2):917-15.

799   139.   van Gerwen M, Alsen M, Little C, Barlow J, Naymagon L, Tremblay D, et al. Outcomes of patients

800   with hypothyroidism and COVID-19: a retrospective cohort study. Front Endocrinol. 2020;11:565.

801   140.   Wang Z, Zheutlin A, Kao Y-H, Ayers K, Gross S, Kovatch P, et al. Hospitalised COVID-19 patients of

802   the Mount Sinai Health System: a retrospective observational study using the electronic medical

803   records. BMJ Open. 2020;10(10):e040441.

804   141.   Yehia BR, Winegar A, Fogel R, Fakih M, Ottenbacher A, Jesser C, et al. Association of race with

805   mortality among patients hospitalized with Coronavirus Disease 2019 (COVID-19) at 92 US

806   hospitals. JAMA Netw Open. 2020;3(8):e2018039.

807   142.   Zafari M, Rad MTS, Mohseni F, Nikbakht N. β-Thalassemia Major and boronavirus-19, mortality

808   and morbidity: a systematic review study. Hemoglobin. 2021;45(1):1-4.

809   143.   Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: characteristics of

810   symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by

811   pregnancy status - United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep.

812   2020;69(44):1641-7.

813   144.   Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Liang L. Association of obesity and its genetic

814   predisposition with the risk of severe COVID-19: analysis of population-based cohort data.

815   Metabolism. 2020;112:154345.

816   145.   Fisman DN, Bogoch I, Lapointe-Shaw L, McCready J, Tuite AR. Risk factors associated with

817   mortality among residents with Coronavirus Disease 2019 (COVID-19) in long-term care facilities in

818   Ontario, Canada. JAMA Netw Open. 2020;3(7):e2015957.

819   146.   Fisman DN, Greer AL, Hillmer M, Tuite R. Derivation and validation of clinical prediction rules for

820   COVID-19 mortality in Ontario, Canada. Open Forum Infect Dis. 2020;7(11):ofaa463.

821   147.   Indigenous Services Canada. Confirmed cases of COVID-19. Ottawa ON: Indigenous Services

822   Canada; 2021. Available from: https://www.sac-isc.gc.ca/eng/1598625105013/1598625167707.

823   148.   Liu M, Maxwell CJ, Armstrong P, Schwandt M, Moser A, McGregor MJ, et al. COVID-19 in long-

824   term care homes in Ontario and British Columbia. CMAJ. 2020;192(47):E1540-E6.

825   149.   Money D. Canadian surveillance of covid-19 in pregnancy: Epidemiology, maternal and infant

826   outcomes. Vancouver, Canada: University of British Columbia; 2021. Available from:

827   https://ridprogram.med.ubc.ca/cancovid-preg/

828   150.   O'Brien J, Du KY, Peng C. Incidence, clinical features, and outcomes of COVID-19 in Canada: impact

829   of sex and age. J Ovarian Res. 2020;13(1):137.

830   151.   O'Brien K, St-Jean M, Wood P, Willbond S, Phillips O, Currie D, et al. COVID-19 death comorbidities

831   in Canada. Ottawa, Canada: Statistics Canada; 2020. Available from:

832   https://www150.statcan.gc.ca/n1/en/pub/45-28-0001/2020001/article/00087-

833   eng.pdf?st=Tj531x2z

834   152.   Panetta L, Proulx C, Drouin O, Autmizguine J, Luu TM, Quach C, et al. Clinical Characteristics and

835   Disease Severity Among Infants With SARS-CoV-2 Infection in Montreal, Quebec, Canada. JAMA

836   Netw Open. 2020;3(12):e2030470.

837   153.   Public Health Agency of Canada COVID-19 Surveillance and Epidemiology Team. Descriptive

838   epidemiology of deceased cases of COVID-19 reported during the initial wave of the epidemic in

839   Canada, January 15 to July 9, 2020. Canada Communicable Disease Report (CCDR).

840   2020;46(10):344-8.

841   154.   Subedi R, Greenberg G, Turcotte M. COVID-19 mortality rates in Canada's ethno-cultural

842   neighbourhoods. Ottawa, Canada: Statistics Canada; 2020. Available from:

843   https://www150.statcan.gc.ca/n1/pub/45-28-0001/2020001/article/00079-eng.htm

844   155.   Wang L, Ma H, Yiu KCY, Calzavara A, Landsman D, Luong L, et al. Heterogeneity in testing,

845   diagnosis and outcome in SARS-CoV-2 infection across outbreak settings in the Greater Toronto

846   Area, Canada: an observational study. CMAJ Open. 2020;8(4):E627-E36.

847   156.   McAlister FA, Bushnik T, Leung AA, Saxinger L. Informing COVID-19 vaccination priorities based on

848   the prevalence of risk factors among adults in Canada. CMAJ. 2021;193(17):E617-21.

849   157.   Jordan RE, Adab P, Cheng KK. COVID-19: risk factors for severe disease and death. BMJ.

850   2020;368:m1198.

851   158.   Arlet J-B, de Luna G, Khimoud D, Odièvre M-H, de Montalembert M, Joseph L, et al. Prognosis of

852   patients with sickle cell disease and COVID-19: a French experience. Lancet Haematol.

853   2020;7(9):e632-e4.

854   159.   de Sanctis V, Canatan D, Corrons JLV, Karimi M, Daar S, Kattamis C, et al. Preliminary data on

855   COVID-19 in patients with hemoglobinopathies: A multicentre ICET-A study. Mediterr J Hematol

856   Infect Dis. 2020;12(1):e2020046-e.

857   160.   Lenti MV, Aronico N, Pellegrino I, Boveri E, Giuffrida P, Borrelli de Andreis F, et al. Depletion of

858   circulating IgM memory B cells predicts unfavourable outcome in COVID-19. Sci Rep.

859   2020;10(1):20836.

860   161.   McClenaghan E, Cosgriff R, Brownlee K, Ahern S, Burgel P-R, Byrnes CA, et al. The global impact of

861   SARS-CoV-2 in 181 people with cystic fibrosis. J Cyst Fibros. 2020;19(6):868-71.

Figure 1. Flow of records through the selection process

OECD=Organization for Economic Cooperation and Development

Table 1. Eligibility criteria for inclusion of studies in the review [a]

	Inclusion and exclusion criteria
Study design	**Include:** − Prospective and retrospective cohort studies, including registry-based studies (may be published as a letter); government reports; pre-prints that have been accepted for publication − Canadian reports of any design − Systematic reviews, only for risk factors of high relevance to NACI where no primary studies are found **Exclude:** Pre-prints that have not been accepted by a peer-reviewed journal, commentaries, editorials
Sample size	Primary studies were required to include at least 1,000 participants (≥300 for studies of children). There was no sample size requirement for systematic reviews.
Population	**Include:** People of any age in the general population; with COVID-19 infection (laboratory-confirmed or epidemiologically linked); hospitalized with COVID-19; with severe COVID-19 (as defined by study authors); children in any of the aforementioned populations. **Exclude:** Populations with other pandemic-related infections, if data for COVID-19 cannot be isolated. People with COVID-19 that is not laboratory-confirmed or epidemiologically linked. When unclear, we included studies if it appeared that the large majority (ie., ≥90%) would be confirmed cases.
Exposure	**Include:** Any P^{2}ROGRESS And Other Factors including but not limited to age; gender identity or sex; disease/condition or disability; number of comorbidities; social factors (place/state of residence; race, ethnicity, immigrant/refugee status, Indigenous identity, culture, language; occupation; religion, belief system; education, literacy; socioeconomic status; social capital); other (e.g., health behaviours). **Exclude:** Exposures that constitute laboratory findings, vital signs, or symptoms occurring after COVID-19 infection; any other exposures not of interest to NACI.
Comparator	**Include:** (a) no exposure to the P^{2}ROGRESS And Other Factors; (b) the same P^{2}ROGRESS And Other Factors experienced differently or to a different extent (e.g., different age group). When included, systematic reviews did not require a comparator. **Exclude:** Variations in disease severity within the pre-existing disease/condition or disability category (i.e., only interested in presence/absence of this risk factor); studies without a comparator.
Outcome	**Include:** Epidemiologic or analytic data from Canadian reports; from all other studies, magnitude of association (based on multivariate analysis adjusting for at minimum age and sex)[*] between the exposure and any of hospitalization; in-hospital length of stay; ICU admission; ICU length of stay; mechanical ventilation; mortality (all-cause or case fatality); severe disease (composite outcomes as defined by study authors); need for rehabilitation; stroke; kidney, liver, or cardiac injury; generic functionality and/or disability (composite scores of validated scales); generic quality of life (composite scores of validated scales). [*]Age and sex needed to be adjusted for at least one pre-existing condition. Pre-existing conditions (except immunocompromised, autoimmune, neurologic, mental health, frailty) needed to be adjusted for body mass index. [b] **Exclude:** All other outcomes; disease-specific functionality, disability, or quality of life; crude / unadjusted associations; studies where the focus is symptoms, biomarkers, clinical variables collected after disease onset.
Timing	Any length of follow-up; at least 28 days for mortality
Setting	− For social risk factors among adults, only Canadian studies − For all other risk factors, Organization for Economic Cooperation and Development countries: https://www.oecd.org/about/document/list-oecd-member-countries.htm − Systematic reviews could include studies from any country
Language	English or French

COVID-19=novel coronavirus 2019; ICU=intensive care unit; NACI=National Advisory Committee on Immunization

Table 2. Summary of study characteristics for the studies contributing to the main synthesis, n=123 [a]

Characteristics	Number of studies	Proportion of studies (%)
STUDIES		
Design		
Retrospective cohort	92	74.8
Prospective cohort	29	23.6
Nested case-control	1	0.8
Systematic review [b]	1	0.8
Setting		
United States	55	44.7
United Kingdom	15	12.2
Mexico	12	9.8
Italy	9	7.3
Korea	6	4.9
Spain	6	4.9
Denmark	4	3.3
France	3	2.4
Other [c]	16	13.0
Funding source		
Non-industry	58	47.2
Industry	3	2.4
No funding	28	22.8
Not reported	36	29.3
PARTICIPANTS [d]		
Number of participants, median (range)	5,279 (34 to 61,414,470)	
Mean or median age in years, median (range)	62.0 (5.0 to 78.6)	
Sex/gender, median % male (range)	49.8 (0 to 94.0)	
Population analyzed		
General population	10	8.1
People with COVID-19	59	48.0
Hospitalized with COVID-19	62	50.4
With severe disease (in ICU or mechanically ventilated)	9	7.3
COVID-19 ascertainment		
RT-PCR	94	76.4
Laboratory confirmed (unspecified test)	25	20.3
Antigen test	3	2.4
Nucleic acid test	2	1.6
Rapid antibody test	2	1.6
EXPOSURES		
Pre-existing conditions	95	77.2
Gender identity/sex	70	56.9
Age (60-69 versus <60 years)	41	33.3
Other (health behaviours)	27	22.0
Number of comorbidities	21	17.1
Children	11	8.9
Exposure - occupation	4	3.3
Pregnancy	4	3.3
OUTCOMES		
Hospitalization	36	29.3

Characteristics	Number of studies	Proportion of studies (%)
In-hospital length of stay	4	3.3
ICU admission	27	22.0
ICU length of stay	1	0.8
Mechanical ventilation	22	17.9
Acute kidney injury	8	6.5
Ischemic stroke	1	0.8
Severe disease	28	22.8
Mortality	88	71.6

COVID-19=novel coronavirus disease 2019; ICU=intensive care unit; RT-PCR=reverse transcription polymerase chain reaction

[a] Categories do not all add to 100%, as it is possible for studies to report on more than one category (e.g., used more than one COVID-19 ascertainment method, analyzed more than one population).

[b] Included for ß-thalassemia as no primary studies meeting the selection criteria were located.

[c] Includes Belgium (n=1), , Germany (n=2), Ireland (n=1), multi-country (n=3), Netherlands (n=1), Sweden (n=2), Turkey (n=2), UK and Italy (n=1).

[d] 24 studies did not report on patient mean or median age, one study in children did not report on patient sex/gender.

Table 3. Risk factors identified that have large or very large associations with severe outcomes of COVID-19 and the corresponding level of certainty in the association

Risk factor (among people with COVID-19 unless otherwise specified)	Outcome of interest	Magnitude of association [a] (certainty in association) [b]
Age		
60-69 vs. <60 years	Hospitalization	Large (moderate)
	Mechanical ventilation	Large (low)
	Severe disease	Large to very large (low)
	Mortality	Large/very large (moderate/low)
Pre-existing conditions		
2 or more vs. no comorbidities	Hospitalization	Large (moderate)
	ICU admission	Large (low)
	Mechanical ventilation	Large (low)
	Mortality	Large (moderate)
Down syndrome [c]	Hospitalization	Large/very large (moderate/low)
	Mortality	Very large (moderate)
Type 1 diabetes [c]	Mortality	Large/very large (moderate/low)
Type 2 diabetes [c]	Mortality	Large/very large (moderate/low)
End-stage kidney disease [c]	Mortality	Large (moderate)
Motor neuron disease, multiple sclerosis, myasthenia gravis, or Huntington's disease [c, d]	Mortality	Large (moderate)
Chemotherapy in the past 12 months (Grade A-C) [c, e]	Mortality	Large/very large (low)
Radiotherapy in the past 6 months [c]	Mortality	Large (low)
Among people <70 years, metastatic cancer	Mortality	Large (low)
Parkinson's disease [c]	Mortality	Large (low)
Sickle cell disease or severe immunodeficiency [c]	Mortality	Large (low)
Solid organ transplant	Mortality	Large (low)
Transplant (any, including solid organ)	Hospitalization	Large (low)
Kidney transplant (due to stage 5 kidney disease) [c]	Mortality	Large (low)
Recent bone marrow or stem cell transplant [c]	Mortality	Large (low)
Vasculitis [c]	Hospitalization	Large (low)
Major psychiatric disorder (schizophrenia, schizoaffective disorder, or bipolar disorder) [f]	Mortality	Large (low)
	Hospitalization	Large (low)
Cerebral palsy [c]	Mortality	Large (low)
Diabetes (any type) in females	Mortality	Large (low)
Obesity class III vs. normal weight	Mortality	Large (low)
Previous cerebrovascular accident	Hospitalization	Large (moderate)
Obesity (all classes) vs. normal weight [c]	Hospitalization	Large (low)
Obesity class III vs. lower body mass index	Hospitalization	Large (low)
Obesity hypoventilation syndrome	Mechanical ventilation	Large (low)
Pregnancy (any stage)	Hospitalization	Large (low)
	ICU admission	Large (low)
	Severe disease (pneumonia)	Large (low)
Frailty [c, g]	Hospitalization	Large (low)
Chronic kidney disease	Hospitalization	Approaching large (low)
Diabetes (any)	Hospitalization	Approaching large (low)
Children (as defined by individual studies)		

Risk factor (among people with COVID-19 unless otherwise specified)	Outcome of interest	Magnitude of association [a] (certainty in association) [b]
Children (0-19 years) vs. adults (50-59 years)	Hospitalization	Large reduction (low)
Age <1 month vs. >1 month	ICU admission	Large (low)
Immunodeficiency or immunosuppression (unspecified reason)	Mortality	Large to very large (low)
	Hospitalization	Large (low)
Hypertension	Hospitalization	Large (low)
2 or more vs. no chronic conditions [h]	Hospitalization	Large (moderate)
1 vs. no chronic conditions [h]	Hospitalization	Large (low)
1 or more vs. no chronic conditions [i]	ICU admission	Large (low)
	Mechanical ventilation	Large (low)
	Severe disease	Large (low)
Asthma	ICU admission	Large (low)
Endocrine condition [j]	Severe disease	Large (low)
Metabolic condition [j]	Severe disease	Large (low)
Malignancy [j]	Severe disease	Large (low)
Black race/ethnicity vs. White non-Hispanic	Mortality	Large (low)
	Hospitalization	Large (low)
Risk of exposure - occupation		
Healthcare workers (vs. non-healthcare workers)	Hospitalization	Large reduction (low)
	ICU admission	Large reduction (low)

ICU=intensive care unit; vs.=versus

[a] Magnitude of associations are shown as large (OR or RR ≥2.00, or ≤0.5 for reduction) or very large (OR or RR ≥4.00).

[b] Confidence in the magnitude of the associations was determined by considering primarily consistency in findings across studies, directness of the setting and risk factors (e.g., type of healthcare system, uncertainty about risk factor clearly matching review criteria), precision (e.g., confidence intervals indicating possibility of little to no association), and potential risk of bias. Low confidence indicates that there may be an association and moderate means that the evidence indicates that there probably is an association of the magnitude stated.

[c] The denominator for these risk factors is the general population. These were included when findings for the risk factor-outcome comparison were not available from studies of populations with COVID-19.

[d] These conditions were grouped within a single study; evidence for the individual conditions is either unavailable or of lower certainty.

[e] There was evidence of a large to very large increase in mortality with grades B and C chemotherapy from one large study. However, the stages of chemotherapy were not defined, and could not be ascertained from the study's authors. In the absence of adequate information, we have grouped all stages of chemotherapy (A, B, and C) together for analysis.

[f] Defined by hospital discharge diagnosis, in combination with drug use (filled a prescription) for the condition in the past 6 months.

[g] General population sample that may include community and non-community dwelling people. Measured on scales that include items such as weight loss, exhaustion, physical activity, walking speed, grip strength, overall health, disability, presence of disease, dementia, falls, mental wellbeing.

[h] Includes congenital malformations, asthma, epilepsy, complex genetic syndromes, endocrine disorders, cancers, hematologic diseases, rheumatic diseases, autoimmune disease, autism or neurologic development impairment, gastrointestinal diseases, liver disease, renal disease, genitourinary diseases, cystic fibrosis or other chronic lung diseases, metabolic disorders, hydrocephalus, severe obesity, hypertension, otolaryngolic diseases, pregnancy, and 'complex chronic conditions'.

[i] Includes congenital malformations, asthma, epilepsy, complex genetic syndromes, endocrine disorders, cancers, hematologic diseases, rheumatic diseases, autism or neurologic development impairment, gastrointestinal diseases, genitourinary diseases, renal disease, cystic fibrosis or other chronic lung diseases, metabolic disorders, hydrocephalus, severe obesity, otolaryngolic diseases.

[j] Categorizations according to ICD-10-CM codes and the Pediatric Medical Complexity Algorithm.

Table 4. Risk factors identified in Canadian reports and potential associations with severe outcomes of COVID-19

Risk factor	Reports (participants)	Conclusion
Social factors		
Living in long-term care	6 (≈2 million)	Probably associated with a large increase in mortality; the association may be very large for those in their 60s and 70s.
Being part of a visible minority population [a]	1 (8,796)	May be associated with increased mortality; magnitude uncertain and findings rely on ecological data and did not account for important covariates.
Living on a First Nations reserve	1 (9,715)	Rates of hospitalization and mortality appear lower compared to living off-reserve. The evidence does not account for potentially important covariates such as age.
Being a healthcare worker	2 (23,101)	Among those aged 30-70 years, may be associated with a large reduction in hospitalization, ICU admission, and mortality. Among healthcare workers, males appear to have higher rates of hospitalization, ICU admission, and mortality than females. Analyses did not account for important covariates.
Homelessness	2 (18,224)	Very uncertain about associations with mortality.
Being a homeless shelter worker	1 (1,734)	Very uncertain about associations with mortality.
Age and gender identity/sex		
Age 60-69 vs. <60 years	5 (235,481)	May be associated with a large increase in hospitalization, ICU admission, and mortality. For mortality there may also be a large association when compared to 50-59 years. The magnitude of association appears to account for pre-existing medical conditions and seems similar between sexes, though absolute rates are high among men in all age groups, particularly among those not residing in long-term care or delivering healthcare. Findings for hospitalization and ICU admission may be most applicable to those living outside of long-term care as there has been limited transfer to hospital and ICU from this setting.
Male vs. female	2 (11,259)	Rates of hospitalization and ICU admission appear to be lower among females >30 years; after excluding health care workers, long-term care residents, and school/daycare workers and attendees, the reduction in hospitalization and ICU admission was only observed in those >50 years. Case fatality appears to be lower among females than males in the same age group.
Pre-existing conditions		
One vs. no comorbidities	2 (15,875)	In all age groups, may have little-to-no association with mortality.
Two or more vs. <2 comorbidities	1 (6,350)	Among people aged 60-79 years, may be associated with a large increase in mortality. Study data were not adjusted for important covariates like residing in long-term care. Findings for people <60 years were limited by small sample size.
Compromised immunity	1 (1,734)	May be associated to some extent with an increase in mortality; the magnitude of association is uncertain due to a wide confidence interval. This association was adjusted for age, long-term care residency, smoking, renal disease, diabetes, and chronic obstructive pulmonary disease.
Malignancy	2 (11,259)	May be associated to some extent with an increase in mortality; the magnitude of association is uncertain due to lack of adjustment for important covariates.

Risk factor	Reports (participants)	Conclusion
Pre-existing chronic conditions	2 (11,259)	Chronic obstructive pulmonary disease, diabetes, and renal disease may be associated with a large increase in mortality; these findings lacked adjustment for sex, BMI, or social factors, which may be important confounders. Other pre-existing conditions that are common among COVID-19 deaths include dementia and Alzheimer's disease, pneumonia, hypertension, ischemic heart disease, respiratory failure, renal failure, chronic lower respiratory disease, nervous system disorders, and cancer. These findings are from epidemiologic data and not adjusted for important covariates.
Special populations		
Pregnancy	1 (137,901)	Among females of childbearing age with COVID-19, pregnancy may be associated with a large-to-very large increase in hospitalization and ICU admission. The findings were not adjusted for important covariates.
Children and young adults		
Pre-existing disease in young people	1 (9,525)	Among young adults, adolescents, and children, mortality from COVID-19 may be associated with having at least one comorbidity. This finding is not adjusted for important covariates.
Pre-existing disease in infants <1 year old	1 (27)	Among a small sample of infants with COVID-19, few (20%) who were hospitalized had a comorbid condition. The findings were not adjusted for any covariates.
Age in infants <1 year old	1 (27)	There appeared to be little-to-no difference in severe outcomes by age. The findings were not adjusted for any covariates.
Sex/gender in infants <1 year old	1 (27)	Among a small sample of infants with COVID-19, half of those hospitalized were male and half were female. The findings were not adjusted for any covariates.

COVID-19=novel coronavirus disease 2019; BMI=body mass index; ICU=intensive care unit

[a] Defined as "Persons, other than Aboriginal peoples, who are non-Caucasian in race or non-white in colour." Includes mainly South Asian, Chinese, Black, Filipino, Latin American, Arab, Southeast Asian, West Asian, Korean, Japanese.